GLOW Blend (BPC-157 + TB-500 + GHK-Cu) vs TB-500
GLOW Blend (BPC-157 + TB-500 + GHK-Cu) (Multi-component research blend) and TB-500 (Actin-binding peptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | GLOW Blend (BPC-157 + TB-500 + GHK-Cu) | TB-500 |
|---|---|---|
| Compound class | Multi-component research blend | Actin-binding peptide fragment |
| Research category | Cosmetic & Dermal | Healing & Recovery |
| Length (amino acids) | Not documented | 7 amino acids |
| Molecular weight | Not documented | ~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form |
| Half-life | Not documented | ~2-3 hours (elimination); tissue effects reported to persist for days |
| Origin | GLOW is a marketed research blend combining BPC-157, TB-500, and GHK-Cu. It is not a naturally occurring substance and exists only as a formulated combination whose exact composition may vary by supplier. | TB-500 is a synthetic peptide commonly described as corresponding to the actin-binding domain (a short fragment, often the LKKTETQ region) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is produced synthetically and is not identical to full-length Thymosin Beta-4. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How GLOW Blend (BPC-157 + TB-500 + GHK-Cu) works
As a blend, GLOW combines the documented properties of its components: BPC-157's angiogenesis and growth-factor-related repair signaling, TB-500's actin regulation and cell-migration activity, and GHK-Cu's copper-delivery and extracellular-matrix remodeling signaling. These properties derive from separate preclinical and cosmetic research; the combined formulation itself is not validated in controlled human trials.
How TB-500 works
Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
TB-500
What sets each apart
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
GLOW is oriented toward combined skin and tissue-repair research, adding the copper tripeptide GHK-Cu to the BPC-157/TB-500 pairing found in simpler blends.
TB-500
TB-500 is defined by its actin-binding fragment identity, distinguishing it from BPC-157's growth-factor/angiogenesis focus and from copper tripeptides used cosmetically.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is the GLOW blend?
The GLOW blend is a research-peptide combination of BPC-157, TB-500, and GHK-Cu. Each component targets a different aspect of tissue and skin remodeling, and the blend is studied together rather than as a single approved drug.
What does each component contribute?
In research framing, BPC-157 is associated with angiogenesis (new blood-vessel growth) at injury sites, TB-500 with actin regulation and migration of repair cells, and GHK-Cu with copper delivery and collagen/elastin matrix remodeling. The rationale is complementary, non-overlapping mechanisms.
What ratio is the GLOW blend usually sold in?
Many GLOW research products are pre-blended in a 5:1:1 ratio of GHK-Cu to TB-500 to BPC-157 (for example 50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157 per vial). Ratios vary by supplier, so the certificate of analysis should be checked for the exact amounts.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is a research peptide associated with thymosin beta-4 (Tbeta4), a 43-amino-acid actin-binding regulatory peptide. The name TB-500 is used in the research-chemical market for both full-length thymosin beta-4 (MW ~4921 Da) and, in some references, the acetylated active fragment covering residues 17-23 (Ac-LKKTETQ). Buyers should check each vendor's COA, since what is shipped as 'TB-500' varies.
What is TB-500 studied for?
In animal models it is researched for tissue repair, wound healing, angiogenesis, and cell migration, largely through thymosin beta-4's role in sequestering G-actin and regulating the actin cytoskeleton. It has also been examined in cardiac and corneal repair models. Human clinical efficacy has not been established.
What does TB-500's half-life imply for research protocols?
Reported elimination half-life is roughly 2-3 hours, but downstream tissue effects are described as persisting for days through signaling cascades. Because of this, research protocols typically use infrequent dosing (e.g. a few times per week) rather than daily, loading over several weeks before a maintenance phase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.